Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions

AIDS and Behavior

Volumn 20, Issue 7, 2016, Pages 1541-1548

  Minnis, Alexandra M ^a,b   van der Straten, Ariane ^a,c   Salee, Parichat ^d   Hendrix, Craig W ^e  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; HIV prevention; Medication adherence; Pre exposure prophylaxis

Indexed keywords

AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TABLET; TENOFOVIR;

ADMINISTRATION AND DOSAGE; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; BLOOD; CROSSOVER PROCEDURE; FEMALE; HIV INFECTIONS; HUMAN; MEDICATION COMPLIANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; PATIENT PREFERENCE; PRE-EXPOSURE PROPHYLAXIS; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; TABLET; TOPICAL DRUG ADMINISTRATION; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CROSS-OVER STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE; PRE-EXPOSURE PROPHYLAXIS; TABLETS; TENOFOVIR; UNITED STATES; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84929440761     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-015-1081-3     Document Type: Article

References (28)

1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New Engl J Med. 2012;367(5):423–34.
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl J Med. 2012;367(5):399–410.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med. 2010;363(27):2587–99.
4. Centers for Disease C, Prevention. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR. Morb Mortal Wkly Rep. 2013;62(23):463–5.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. New Engl J Med. 2012;367(5):411–22.
7. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Conference on retroviruses and opportunistic infections, Atlanta, GA, 2013.
8. Rees H, Delany-Moretlwe S, Baron D, Lombard C, Gray G, Myer L et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. In: Abstract #26LB presented at CROI, Seattle, WA, 2015.
9. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–9.
10. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep. 2013;10(1):89–102.
11. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2013;44(1 Suppl 2):S91–8.
12. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women. Conference on retroviruses and opportunistic infections, Seattle, WA, 2012.
13. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.
14. Koblin BA, Andrasik M, Austin J. Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions. J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S183–6.
15. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59(5):463–8.
16. Gorbach PM, Kelly CW, Borgerding JA, Ramjee G, Tembo T, Kumwenda N, et al. Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035). AIDS Behav. 2013;18(5):855–61.
17. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737–47.
18. Dayton R, Lanham M, Wilcher R. Engaging male partners in women’s microbicide use. FHI 360, 2014.
19. Montgomery CM, Lees S, Stadler J, Morar NS, Ssali A, Mwanza B, et al. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care. 2008;20(6):733–40.
20. Gengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2013;36(1):70–85.
21. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118.
22. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013;8(1):e55013.
23. Donnell D, Baeten J, Hendrix C, Bumpus N, Bangsberg D, Haberer J, et al., editors. Tenofovir drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects. 19th Conference on retroviruses and opportunistic infections, Seattle, WA, 2012.
24. Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1 % tenofovir gel. PLoS One. 2011;6(10):e25974.
25. Grant R, editor. Completed observation of the randomized placebo-controlled phase of iPrEx: daily oral FTC/TDF pre-exposure HIV prophylaxis among men and trans women who have sex with men. Sixth IAS Conference, Rome, Italy, 2011.
26. United Nations Children’s Fund. Towards an AIDS-free generation—children and AIDS: sixth stocktaking report. New York: United Nations Children’s Fund, UNICEF; 2013.
27. Montgomery ET, Chidanyika A, Chipato T, van der Straten A. Sharing the trousers: gender roles and relationships in an HIV-prevention trial in Zimbabwe. Cult Health Sex. 2012;14(7):795–810.
28. Plummer ML, Watson-Jones D, Lees S, Baisley K, Matari S, Changalucha J, et al. A qualitative study of participant adherence in a randomized controlled trial of herpes suppressive therapy for HIV prevention in Tanzania. AIDS Care. 2010;22(4):499–508.